NCYM, a Cis-antisense gene of MYCN, encodes a de novo evolved protein that inhibits GSK3β resulting in the stabilization of MYCN in human neuroblastomas

PLoS Genet. 2014 Jan;10(1):e1003996. doi: 10.1371/journal.pgen.1003996. Epub 2014 Jan 2.

Abstract

The rearrangement of pre-existing genes has long been thought of as the major mode of new gene generation. Recently, de novo gene birth from non-genic DNA was found to be an alternative mechanism to generate novel protein-coding genes. However, its functional role in human disease remains largely unknown. Here we show that NCYM, a cis-antisense gene of the MYCN oncogene, initially thought to be a large non-coding RNA, encodes a de novo evolved protein regulating the pathogenesis of human cancers, particularly neuroblastoma. The NCYM gene is evolutionally conserved only in the taxonomic group containing humans and chimpanzees. In primary human neuroblastomas, NCYM is 100% co-amplified and co-expressed with MYCN, and NCYM mRNA expression is associated with poor clinical outcome. MYCN directly transactivates both NCYM and MYCN mRNA, whereas NCYM stabilizes MYCN protein by inhibiting the activity of GSK3β, a kinase that promotes MYCN degradation. In contrast to MYCN transgenic mice, neuroblastomas in MYCN/NCYM double transgenic mice were frequently accompanied by distant metastases, behavior reminiscent of human neuroblastomas with MYCN amplification. The NCYM protein also interacts with GSK3β, thereby stabilizing the MYCN protein in the tumors of the MYCN/NCYM double transgenic mice. Thus, these results suggest that GSK3β inhibition by NCYM stabilizes the MYCN protein both in vitro and in vivo. Furthermore, the survival of MYCN transgenic mice bearing neuroblastoma was improved by treatment with NVP-BEZ235, a dual PI3K/mTOR inhibitor shown to destabilize MYCN via GSK3β activation. In contrast, tumors caused in MYCN/NCYM double transgenic mice showed chemo-resistance to the drug. Collectively, our results show that NCYM is the first de novo evolved protein known to act as an oncopromoting factor in human cancer, and suggest that de novo evolved proteins may functionally characterize human disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antisense Elements (Genetics) / genetics*
  • Cell Line, Tumor
  • Gene Amplification
  • Gene Expression Regulation, Neoplastic
  • Glycogen Synthase Kinase 3 / genetics*
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • Mice
  • Mice, Transgenic
  • N-Myc Proto-Oncogene Protein
  • Neoplasm Proteins / genetics*
  • Neuroblastoma / etiology
  • Neuroblastoma / genetics*
  • Neuroblastoma / pathology
  • Nuclear Proteins / genetics*
  • Nuclear Proteins / metabolism
  • Oncogene Proteins / genetics*
  • Oncogene Proteins / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • RNA, Messenger / genetics

Substances

  • Antisense Elements (Genetics)
  • MYCN protein, human
  • MYCNOS protein, human
  • N-Myc Proto-Oncogene Protein
  • Neoplasm Proteins
  • Nuclear Proteins
  • Oncogene Proteins
  • RNA, Messenger
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, mouse
  • Glycogen Synthase Kinase 3

Grants and funding

This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for the Third Term Comprehensive Control Research for Cancer, Japan (AN), a Grant-in-Aid for Scientific Research on Priority Areas (JSPS KAKENHI Grant Number 17015046) (AN), a Grant-in-Aid for Scientific Research (A) (JSPS KAKENHI Grant Number 24249061) (AN), a Grant-in-Aid for Research Activity start-up (JSPS KAKENHI Grant Number 22890241) (YS) and a Grant-in-Aid for Young Scientists (B) (JSPS KAKENHI Grant Number 24700957) (YS) from the Japan Society for the Promotion of Science (JSPS), a Global COE program (Global Center for Education and Research in Immune System Regulation and Treatment), Graduate School of Medicine, Chiba University (AN and YS), Takeda Science Foundation (AN), and National Cancer Center Research and Development Fund (23-A-8) (TS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.